NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.
 
Reference is made to NorDiag ASAs ("NorDiag" or the "Company") stock exchange announcement 12 October 2011 regarding the rights issue and the issuance of warrants.
 
Enclosed are the minutes from the Extraordinary General Meeting in NorDiag ASA held today, 2 November 2011.
 
32,499,257 of a total of 68,603,145 shares and votes were represented at the General Meeting, or approximately 47.4% of the share capital.
 
All resolutions were made in accordance with the Board of Directors' proposals.
 
For further information, please contact:
CEO Mårten Wigstøl,  Phone. +47 911 65775
CFO Tone Kvåle,  Phone: +47 915 19576
 

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden and in Atlanta (GA), USA. The group has today 31.6 man-labour years. NorDiag is listed on the Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com.
 
 
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Minutes from EGF

Read the noice in Norwegian here.